Coagulation element VIIa is a man-made protein like a characteristic protein in the body that helps the blood to clump.

Coagulation element VIIa is utilized to treat or avert seeping in individuals with hemophilia An or hemophilia B, or variable VII insufficiency.

Coagulation element VIIa may likewise be utilized for purposes not recorded as a part of this pharmaceutical aide.

Submit your review

Create your own review

Average rating:  
 0 reviews
  • NovoSeven RT, NovoSeven RTwith MixPro
  • Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

    Call your doctor at once if you have:

    sudden numbness or weakness, especially on one side of the body;
    sudden severe headache, confusion, problems with vision, speech, or balance;
    chest pain, sudden cough, wheezing, rapid breathing, coughing up blood;
    pain, swelling, warmth, or redness in one or both legs;
    little or no urinating;
    a feeling that you might pass out; or
    any bleeding that will not stop.
    Common side effects may include:

    mild headache;
    joint pain;
    nausea, vomiting;
    mild itching or rash; or
    pain, redness, swelling, or irritation where the medicine was injected.
  • The recommended dose range for the treatment of patients with acquired hemophilia is 70-90 micrograms/kg repeated every 2-3 hours until hemostasis is achieved. The minimum effective dose in acquired hemophilia has not been determined. The majority of the effective outcomes were observed with treatment in the recommended dose range. The largest number of treatments with any single dose was 90 micrograms/kg; of the 15 treated, 10 (67%) were effective and 2 (13%) were partially effective.